Literature DB >> 27261586

Advances in biomarkers of biliary tract cancers.

Jun Hu1, Baobing Yin2.   

Abstract

Tumor biomarkers can be applied for early diagnosis or precise treatment, thereby leading to personalized treatment and better outcomes. Biliary tract cancers (BTCs) are a group of cancers that occurs in different locations and have different clinical or genetic properties. Though the incidence of BTCs is rare, BTCs are among the most lethal cancers in the world and all have very low 5-year survivals. Lack of efficient early diagnostic approaches or adjuvant therapies for BTCs are main reasons. These urge us to broaden the researches into BTC biomarkers. Although few progresses of diagnostic biomarkers for BTCs have been achieved, there are still some advances in prognostic, predictive and therapeutic areas. In this review, we will focus on these achievements.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biliary tract cancer; Biomarker; Cholangiocarcinoma; Gallbladder cancer

Mesh:

Substances:

Year:  2016        PMID: 27261586     DOI: 10.1016/j.biopha.2016.02.045

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

2.  The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Authors:  Jianchun Xiao; Li Wang; Tao Hong; Binglu Li; Wei Liu; Qiang Qu; Chaoji Zheng; Xiaodong He
Journal:  J Oncol       Date:  2021-02-23       Impact factor: 4.375

3.  CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma.

Authors:  Sven H Loosen; Christoph Roderburg; Katja L Kauertz; Alexander Koch; Mihael Vucur; Anne T Schneider; Marcel Binnebösel; Tom F Ulmer; Georg Lurje; Wenzel Schoening; Frank Tacke; Christian Trautwein; Thomas Longerich; Cornelis H Dejong; Ulf P Neumann; Tom Luedde
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

4.  Ceruloplasmin as a prognostic marker in patients with bile duct cancer.

Authors:  In Woong Han; Jin-Young Jang; Wooil Kwon; Taesung Park; Yongkang Kim; Kyoung Bun Lee; Sun-Whe Kim
Journal:  Oncotarget       Date:  2017-04-25

5.  Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma.

Authors:  Chaobin He; Yu Zhang; Yunda Song; Jun Wang; Kaili Xing; Xiaojun Lin; Shengping Li
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

6.  Identification and Validation of Three Autophagy-Related Long Noncoding RNAs as Prognostic Signature in Cholangiocarcinoma.

Authors:  Ya Jun Liu; Alphonse Houssou Hounye; Zheng Wang; Xiaowei Liu; Jun Yi; Min Qi
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

7.  Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma.

Authors:  Hanyu Li; Junyu Long; Fucun Xie; Kai Kang; Yue Shi; Weiyu Xu; Xiaoqian Wu; Jianzhen Lin; Haifeng Xu; Shunda Du; Yiyao Xu; Haitao Zhao; Yongchang Zheng; Jin Gu
Journal:  Oncol Rep       Date:  2019-09-17       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.